Page last updated: 2024-09-27
Cone Dystrophy
A general term which describes a group of rare eye disorders that affect the cone cells of the RETINA. Cone dystrophy can cause a variety of symptoms including decreased visual clarity or acuity when looking straight ahead (central vision), a reduced ability to see colors, and an increased sensitivity to light (PHOTOPHOBIA).
Synonyms(3)
| Synonym |
|---|
| Progressive Cone Dystrophy |
| Cone Dystrophy |
| Stationary Cone Dystrophy |
Research
Studies (3)
| Timeframe | Studies, This Condition (%) | All Conditions % |
|---|---|---|
| pre-1990 | 0 (0.00) | 23.3326 |
| 1990's | 0 (0.00) | 12.5806 |
| 2000's | 0 (0.00) | 18.1394 |
| 2010's | 0 (0.00) | 28.8240 |
| 2020's | 3 (100.00) | 9.53 |
Drugs Studied (4)
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| fomesafen | 0 | low | 1 | 0 |
| 11-cis-retinal | 0 | low | 1 | 0 |
| cyclic gmp | 0 | low | 1 | 0 |
Protein Targets (17)
| Protein | Potency Measurements | Inhibition Measurements | Activation Measurements | Drugs |
|---|---|---|---|---|
| Chain A, Retinaldehyde-binding protein 1 | 0 | 0 | 1 | 1 |
| Chain A, Retinaldehyde-binding protein 1 | 0 | 0 | 1 | 1 |
| Phosphodiesterase | 0 | 1 | 0 | 1 |
| Multidrug resistance-associated protein 4 | 0 | 0 | 0 | 1 |
| Multidrug resistance-associated protein 5 | 0 | 0 | 0 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | 0 | 1 | 0 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | 0 | 1 | 0 | 1 |
| Luciferase | 1 | 0 | 0 | 1 |
| hypoxia-inducible factor 1 alpha subunit | 1 | 0 | 0 | 1 |
| progesterone receptor | 1 | 0 | 0 | 1 |
| estrogen-related nuclear receptor alpha | 1 | 0 | 0 | 1 |
| pregnane X nuclear receptor | 1 | 0 | 0 | 1 |
| estrogen nuclear receptor alpha | 1 | 0 | 0 | 1 |
| peroxisome proliferator activated receptor gamma | 1 | 0 | 0 | 1 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | 1 | 0 | 0 | 1 |
| Histone H2A.x | 1 | 0 | 0 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | 1 | 0 | 0 | 1 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | ||||